Rochester Medical — Investor Presentation (August 2013)
25 slides from Rochester Medical's investor presentation, Aug 1, 2013
Slide 1: Summer 2013 Rochester Medical Corporation Investor Presentation
Summer 2013 Rochester Medical Corporation Investor Presentation
Slide 2: Outline
Outline . Company Overview . Investment Considerations . Global Revenue Growth Trend . Sound Growth Strategy . Market Opportunity & Product Lines . Financial Summary & Outlook 2
Slide 3: Company Overview
Company Overview . Founded in 1988 . Develop, manufacture and market innovative disposable incontinence and bladder drainage products . Advanced technology company with deep & growing patent portfolio . Vertically integrated with strong R&D and proprietary manufacturing capabilities . Global sales &
Slide 4: Investment Considerations
Investment Considerations . Mid-teens revenue growth & doubling of net income this fiscal year . Superior technologies enable market share gains in large global markets . Favorable reimbursement changes support our technologies . Seasoned US sales team & broad international distribution . Recent div
Slide 5: Global Revenue Growth: Driven by Accelerating Direct Sales, US & OUS
Global Revenue Growth: Driven by Accelerating Direct Sales, US & OUS *F09 if £ to $ exchange rates had not fallen (1.966 – 1.558) 5 $0 $10 $20 $30 $40 $50 $60 $70 FY05 FY06 FY07 FY08 FY09* FY10 FY11 FY12 FY13E Direct Sales: Non-Foley Private Label Direct Sales: Foley
Slide 6: Sound Growth Strategy: Drive Sales, Profit & Cash Flow Improvements
Sound Growth Strategy: Drive Sales, Profit & Cash Flow Improvements . Deliver mid-teens top-line growth* . Paced by robust U.S. and U.K. Direct Sales growth, up 18% and 23%, respectively, year-to-date fiscal 2013 . Other international Direct Sales markets growing modestly . Moderate Private Label sa
Slide 7: Global Market Opportunities: Superior Products Drive Share Capture
Global Market Opportunities: Superior Products Drive Share Capture (US$, millions) Product U.S. Market Europe Market Total Global Market Estimated Market 5 Year CAGR (%) ROCM Global Market Share (%) Key Competitors Intermittent Catheters $400 $400 $800 Low single digits <3% Coloplast, Hollister Male
Slide 8: Innovative Products
Innovative Products Products Features & Benefits Intermittent Catheters Magic3 & Hydrosil • 3-layer construction enables soft, gentle outer layer with firm inner layer for easy insertion & removal • Silicone (non-latex) • Hydrophilic, antibacterial & phthalate-free Male External Catheters Spirit™ Hy
Slide 9: Intermittent Catheters
Intermittent Catheters 9 . Biggest growth driver for Rochester Medical . Gaining share in $800 million growing worldwide market
Slide 10: Male External Catheters
Male External Catheters 10 . Latex free . Skin-friendly advanced adhesive innovations . Wide array of styles and sizes offers security, confidence and convenience . Spirit™ launched October 2012 . First and only male external catheter to combine the moisture-wicking properties of a hydrocolloid adhe
Slide 11: FemSoft Insert
FemSoft Insert . An elegant & proprietary solution for female stress incontinence . Stress incontinence affects 14 million women in the U.S. . Very positive response from OB/GYNs & urologists . Compelling testimonials from consumers . “FemSoft saved my life!” 11 . U.S. and U.K. reimbursement coverag
Slide 12: Favorable Market Dynamics: Support Growth & Share Gains
Favorable Market Dynamics: Support Growth & Share Gains Products Key Market Drivers Intermittent Catheters • New product features offer measureable patient benefits & attract clinician support • Change in U.S. reimbursement in 2009 allowing 200 catheters/month, up from 4/month • International penetr
Slide 13: Sound Growth Strategy: Major U.S. Sales Force & OUS Presence
Sound Growth Strategy: Major U.S. Sales Force & OUS Presence . Significant U.S. Home Care sales infrastructure . ~21 reps today vs. 3 in 2010 . Steadily increasing share of scripts written • We estimate 1 of every 4 new long-term patient scripts written for Rochester brand product . Direct sales pre
Slide 14: U.S. Sales Force Coverage
U.S. Sales Force Coverage = One sales rep = One regional sales manager 14
Slide 15: Sound Growth Strategy: Expand Internationally to Drive OUS Sales
Sound Growth Strategy: Expand Internationally to Drive OUS Sales . Drive organic growth in existing international markets . Primary markets: Europe & Middle East . Direct sales force located in the U.K. & the Netherlands . Extensive distributor network outside the U.K. . Partnered with Teleflex to s
Slide 16: Global Sales & Distribution: International Sales – 63% of FY12 Total Sales
Blue shading denotes Rochester Medical Direct Sales activity LTM Distribution relationships in 58 countries Rochester Medical-manufactured products marketed in more than 75 countries 16 Global Sales & Distribution: International Sales – 63% of FY12 Total Sales
Slide 17: Sound Growth Strategy: Private Label a Steady Grower
Sound Growth Strategy: Private Label a Steady Grower . Solid relationships with leading medical products customers around the world . Coloplast . Hollister . B. Braun . Quarterly fluctuations in sales growth will diminish as Private-label sales represent a smaller % of total sales 17 YTD FY'13* Priv
Slide 18: Sound Growth Strategy: Divestiture of Foley Catheter Line
Sound Growth Strategy: Divestiture of Foley Catheter Line . Rationale for divestiture: to be a stronger, faster growing & more profitable company . High barriers in Foley market . Extensive manufacturing & marketing costs reduced operating income . Financial implications of divestiture . Near-term:
Slide 19: Recent Quarterly Results (as of 6/30/13)
Recent Quarterly Results (as of 6/30/13) 19 FY End September 3 Months 9 Months (US$, millions) Q3’13 Q3’12 Change FY’13 FY’12 Change Revenues(1) $17.0 $15.4 10% $50.9 $44.8 14% Gross Margin 51.0% 49.6% +140bps 50.2% 49.9% +30bps Operating Expenses $6.9 $6.9 -- $20.6 $20.8 -1% Operating Income $1.7 $
Slide 20: Third Quarter 2013 Highlights
Third Quarter 2013 Highlights . Total Global sales increased 18%* y/y to $17.0 million . Global Direct Sales up 22%* y/y to $13.5 million . Intermittent Catheters up 34% y/y . MECs up 36% y/y . Global Private Label Sales up 5% y/y $3.3 million . GAAP Net Income of $1.1 million ($0.09 per diluted sha
Slide 21: Financial Profile (as of 6/30/13)
Financial Profile (as of 6/30/13) . Strong balance sheet . $26.2 million in cash & marketable securities . $15.4 million working capital (excluding cash) . $5 million available on a $5 million Line of Credit . Zero debt . Positive free cash flow .Will fully-fund construction of new manufacturing fac
Slide 22: Looking Ahead
Looking Ahead . FY13 guidance(excluding Foley Business): . $67 million in revenues, up 17%* . $7 million in after-tax net income** . Expect strong direct Home Care sales growth . Primarily driven by Intermittent Catheter products . U.S. & U.K. strongest growth, complemented by more moderate Europe/R
Slide 23: Summary
Summary . Rochester Medical is focused on delivering solid top line growth and improving profitability . Clear strategy to grow sales . Highly advanced & innovative product portfolio with further advanced products in the pipeline . Large, global markets with opportunities to gain abundant market sha
Slide 24: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” with in the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results of Rochester Medical. Such statemen
Slide 25: [LOGO]
[LOGO]
Rochester Medical — Investor Presentation (August 2013) on 6ix